Highest-materiality recent filing
40 participants dosed; SGT-003 well tolerated with steroid-only immunomodulation regimen.
Solid Biosciences raises ~$240M in private placement; prelim cash ~$188M
Gross proceeds ~$240M from 14.97M shares at $5.61 and 27.81M pre-funded warrants at $5.609.
Cash, cash equivalents and available-for-sale securities: $236.1M as of Sep 30, 2025; runway into H1 2027.
Solid Biosciences reports 110% avg microdystrophin expression from SGT-003 Phase 1/2 trial
First three participants showed average 110% microdystrophin expression by western blot and 78% dystrophin-positive fibers at Day 90.
Solid Biosciences prices $200M underwritten offering; extends cash runway into first half 2027
Priced $200M underwritten offering expected to close Feb 19, 2025; net proceeds to fund R&D for SGT-003 and other candidates.
Solid Biosciences prices $200M public offering of common stock and pre-funded warrants
Priced public offering of 35.7M shares at $4.03/share and pre-funded warrants for 13.9M shares at $4.029 each; gross proceeds ~$200M.
Adam Koppel notified Solid Biosciences Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), effective as of June 11, 2024.
Rajeev Shah notified the Company of his decision to resign as a member of the Board, effective as of June 11, 2024.
Max materiality 0.85 · Median 0.72 · Most common event other_material